Please enable JS

DISCOVER

CT-SCOUT™

Success is when the time to access an innovative treatment is reduced.

CT-SCOUT™ is a multi-device application aiming at facilitating the recruitment of patients in clinical studies...

It assists the investigational team in detecting the studies for which a patient is potentially eligible according to his/her current health conditions.

Access to CT-SCOUT™

The digital solution to boost patient recruitment in clinical trials

Transforms all physician into real time recruiters
Anywhere, anytime
On any device
Easy to use

CT-SCOUT™ unique features

1. An efficient algorithmic model

2. Real-time detection

3. Simplified
process

Therapeutic Expertise

Gastroenterology

Crohn disease
Ulcerative colitis

Dermatology

Psoriasis
Atopic dermatitis
Hidradenitis suppurativa

Rheumatology

Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis

200 +

studies registered (industrial & academic)

1000 +

users registered

170 +

centers in various countries (Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Switzerland, UK…)

7000 +

Patients detected

Figure: Total R&D/clinical trials pipeline size, by year 2000-2022

They are so many drugs in development that it is extremely challenging to finds the way to one of them, as a patient or as a site, or to secure a high visibility on one of them for a Sponsor. CT-SCOUT™and ToTem4me facilitate the match between the patients and the studies.

50%

OF STUDIES FAIL TO MEET PATIENT RECRUITMENT DEADLINES

However, millions of patients visit clinical sites every day.
CT-SCOUT help investigators identify the ones that could benefit from a clinical study.

80%

OF THE PATIENTS WOULD WELCOME THE OPPORTUNITY TO PARTICIPATE TO A CLINICAL STUDY

Patients have become actors of their treatment conditions.
ToTem4me help them identify potential opportunities through clinical studies.

0.02%

OF THE PATIENTS ARE BEING OFFERED TO PARTICIPATE TO A CLINICAL STUDY

But 80% of patients would accept to participate t a clinical study.
CT-SCOUT contributes to increase the percentage of patients considered for clinical research.

2

WEEKS SET-UP TIME

No more than 2 weeks are required to get CT-SCOUT
or ToTem4me deployed for a clinical study

As a summary

Assist investigational teams in their clinical research activities.

Shorten clinical trials by boosting detection of patients potentially eligible to clinical trials.

Allow patients’ earlier access to innovative and life-saving treatment.

LATEST NEWSOUR NEWS >

telemedecine technologies news

Join Telemedicine Technologies at EUCROF26!

October 30, 2025

February 1–3, 2025 – Amsterdam | Booth 16-17-18 We’re excited to announce our participation to EUCROF26! Visit our booth to explore CleanWeb™, our advanced eClinical suite for managing clinical trials, registries, and early access programs. Together with our CRO Alliance partners (BlueCompanion, Clinica Group, DeltaClinical, NextCRO, Phoenix CR), we offer tailored solutions to support your […]

READ MORE
telemedecine technologies news

Bringing Clinical Trials Into the Digital Era with eConsent

October 30, 2025

Applied Clinical Trials Online Clinical trials have traditionally relied on paper-based consent forms to secure the participant’s approval. While this approach is still common in many studies, it presents practical challenges. Participants may struggle with dense medical jargon, documents can be misplaced, and re-consenting often adds to site workload. As decentralized and hybrid trial models […]

READ MORE
telemedecine technologies news

Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care

October 30, 2025

Biopharm International To improve patient outcomes, experience, and engagement, patient-centric drug development is essential. By focusing on patients’ needs, experiences, and preferences, drug developers can create treatments that are optimally effective and tolerated. This leads to improved adherence to treatment regimens and better overall health outcomes when compared with not taking these factors into consideration […]

READ MORE